Avadel Pharmaceuticals (AVDL) Morgan Stanley 23rd Annual Global Healthcare Conference summary

Business transformation and growth

• Achieved cash flow positive status as a commercial-stage biotech, with over 3,100 patients on LUMRYZ and ongoing expansion of prescribers and patient base.

• Recently acquired rights to valiloxybate, expanding the oxybate portfolio and reinforcing a strategic focus on rare sleep disorders.

• Global search for innovative assets, with recent deals including partnerships in Asia, and a focus on addressing unmet patient needs regardless of geography.

• Leveraging AI and advanced analytics across clinical, commercial, and manufacturing operations to enhance predictive capabilities and operational efficiency.

• Onshored manufacturing to the U.S. for supply chain redundancy and tariff mitigation, sourcing all API domestically.

Market landscape and product differentiation

• Estimated 160,000 narcolepsy patients in the U.S., with about 50,000 eligible for oxybate therapy and 4,000-5,000 new oxybate starts annually.

• LUMRYZ offers once-at-bedtime, extended-release oxybate, addressing both nighttime and daytime symptoms, differentiating from wake-promoting agents and twice-nightly oxybates.

• Real-world studies and physician feedback indicate improved outcomes and growing preference for LUMRYZ over older therapies.

• Competitive landscape includes new orexin-2 agonists and mixed salt oxybates, but LUMRYZ is positioned as complementary and preferred for its 24-hour efficacy.

• Growth is driven by switches from older agents, new patient starts, and previously discontinued patients, with half of current patients being switches.

Pipeline and regulatory milestones

• Pivotal phase III trial for idiopathic hypersomnia (IH) expected to complete enrollment by year-end, with top-line data by mid-next year and NDA submission in the second half of 2026.

• Valiloxybate development to begin with PK studies later this year, aiming for final formulation by Q1 next year and NDA filing targeted for 2027.

• Recent favorable litigation outcome allows pursuit of new LUMRYZ indications and ongoing antitrust litigation could yield significant damages.